Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tango Therapeutics (TNGX) EBITDA (2020 - 2025)

Tango Therapeutics has reported EBITDA over the past 6 years, most recently at $48.1 million for Q4 2025.

  • Quarterly results put EBITDA at $48.1 million for Q4 2025, up 217.55% from a year ago — trailing twelve months through Dec 2025 was -$21.3 million (up 84.94% YoY), and the annual figure for FY2025 was -$101.7 million, up 21.86%.
  • EBITDA for Q4 2025 was $48.1 million at Tango Therapeutics, up from $14.1 million in the prior quarter.
  • Over the last five years, EBITDA for TNGX hit a ceiling of $48.1 million in Q4 2025 and a floor of -$42.5 million in Q1 2025.
  • Median EBITDA over the past 5 years was -$27.2 million (2022), compared with a mean of -$21.6 million.
  • Biggest five-year swings in EBITDA: crashed 958162.71% in 2021 and later soared 217.55% in 2025.
  • Tango Therapeutics' EBITDA stood at -$22.8 million in 2021, then dropped by 22.4% to -$27.9 million in 2022, then fell by 7.12% to -$29.9 million in 2023, then tumbled by 36.84% to -$40.9 million in 2024, then soared by 217.55% to $48.1 million in 2025.
  • The last three reported values for EBITDA were $48.1 million (Q4 2025), $14.1 million (Q3 2025), and -$41.0 million (Q2 2025) per Business Quant data.